APC and colorectal cancer: In conclusion, therapeutic inhibition of the WNT/β-catenin pathway in colorectal cancers, which possess in their majority APC mutations but also present, in a significant minority of cases, mutations in other key proteins of the pathway, needs to be developed with these specific alterations taken into consideration.